Here’s what Dipan Mehta of Elixir Equities has to say about telecom, pharma stocks
Summary
We are positive on the pharma industry and Aurobindo is certainly a stock we prefer to buy but it is more for investors who have a really longer term outlook, said Dipan Mehta of Elixir Equities.
Market expert Dipan Mehta of Elixir Equities in an interview with CNBC-TV18 shared his views on certain stocks/sectors.
When asked about telecom space, he said from an an investment perspective, they still prefer Bharti Airtel but think Vodafone-Idea could be a trading pick. “Vodafone-Idea still remains within the purview of traders and from an investment perspective one would still like to avoid it. The correction which has taken place in Bharti Airtel makes it a good solid long-term investment buy and investors can make it as a part of their core holdings.
With regards to IndusInd Bank, Mehta said, “It is really perplexing, we have seen the management come in and say that it is business as usual and they are sitting on lot of liquidity and as such there are no challenges for them- yet the stock keeps on sliding the way it has. This particular resolution for telecom is highly beneficial for IndusInd Bank which has a major exposure to Vodafone but still the stock seems to continuously correct. I think it is just a stock which was greatly in favour over the past decade or so and now it is finally getting out of favour and long term core holdings are getting sold off in IndusInd Bank.”
Talking about Aurobindo Pharma he said, “The usual disclosure is that we and our clients are invested in it. With the associated risk factors about USFDA inspection and all those action whether be it warning letter or import alert, all those are still dangling swords, some of it has got already priced in given that it is amongst the cheapest pharmaceutical stock in its peer group.”
According to him, what investors prefer in Aurobindo Pharma is large scale of backward integration, which means that they have a cost advantage and maybe the expectation that you would have in the next few weeks the approval for the Sandoz acquisition of their generic product, which could be a trigger for Aurobindo Pharma.
“On the whole investors are getting quite favourable and positive on the pharmaceutical industry especially those exporting to US. They will find the environment improve significantly post Coronavirus not only in terms of demand, but maybe hopefully also in terms of regulatory actions which the USFDA may take. So there is a hope that they may be a bit more lenient and quicker in terms of approving ANDA,” he added.
“So from that point of view, we are positive on the pharma industry and Aurobindo is certainly a stock we prefer to buy but it is more for investors who have a really longer term outlook,” said Mehta.
Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout
3 Mins Read
Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter